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Abstract
Background—Folate, other vitamin B cofactors, and genes involved in folate-mediated one-carbon
metabolism (FOCM) all may play important roles in colorectal neoplasia. In this study, we examined
the associations between dietary and circulating plasma levels of vitamins B2, B6 and B12 and risk
colorectal adenomas.
Methods—The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid
supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas
(n=1,084). Diet and supplement use were ascertained through a food-frequency questionnaire
administered at baseline. Blood collected at baseline was used to determine plasma B-vitamin levels.
We used generalized linear regression to estimate risk ratios (RR) and 95% confidence limits (CI)
as measures of association.
Results—We found a borderline significant inverse association with plasma B6 (pyridoxal 5′
phosphate, PLP) and adenoma risk (adjusted RR Q4 vs. Q1=0.78, 95% CI=0.61-1.00, p-trend=0.08).
This association was not modified by folic acid supplementation or plasma folate. However, the
protective association of PLP with adenoma risk was observed only among subjects who did not
drink alcohol (p-interaction=0.03). Plasma B2 (riboflavin) was inversely associated with risk of
advanced lesions (adjusted RR Q4 vs. Q1=0.51; 95% CI=0.26-0.99, p-trend=0.12). No significant
associations were observed between adenoma risk and plasma vitamin B12 or dietary intake of
vitamin B2 and B6. When we examined specific gene-B-vitamin interactions, we observed a possible
interaction between MTHFR-C677T and plasma B2 on risk of all adenomas.
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Conclusion—Our results suggest that high levels of PLP and B2 may protect against colorectal
adenomas.
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Introduction
Folates play potentially important roles in carcinogenesis because of their role as major carriers
of the one-carbon groups needed for intracellular methylation reactions and nucleotide
synthesis (1,2). Folate-associated one-carbon metabolism (FOCM) depends on B-vitamin co-
factors for many of the key reactions involved. Thus methylenetetrahydrofolate reductase
(MTHFR) requires vitamin B2 (riboflavin), the reactions catalyzed by methionine synthase
reductase (MTRR) and methionine synthase (MTR) require vitamin B12 (cyanocobalamin) and
cystathionine-β-synthase (CBS) requires vitamin B6 (pyridoxine). However, understanding of
the relationships between B-vitamins and risk of incident colorectal adenomas is limited.
The role of vitamins B2, B6, and B12, particularly dietary intake, has been investigated in several
studies of colorectal adenomas and cancer. In the majority of studies, intake of vitamin B2
(3-7) and vitamin B12 (3,5,6,8-12) have been unassociated with colorectal adenoma or cancer
risk. However, there is stronger evidence to support an inverse association between dietary
vitamin B6 and risk of colorectal adenomas or cancer (3,4,12-17). In addition, levels of the
main active form of circulating B6, pyridoxal 5′phosphate (PLP), were found to be inversely
associated with risk of colon cancer in the Nurses’ Health Study (14).
Other studies have investigated whether selected polymorphisms in FOCM genes coding for
enzymes that require B-vitamins as co-factors modify the relationship between dietary intake
of the vitamins and risk of colorectal adenomas or cancer, but results have been inconsistent
(5,6,18-25). A few studies have also reported on the role of polymorphic FOCM genes on risk
of adenomas in individuals with a previous history of adenomas (26,27), but have not yet
explored the inter-relationships between these polymorphisms and intake or blood levels of B-
vitamins.
In this randomized clinical trial of aspirin use and folic acid supplementation, we examined
the associations of baseline plasma levels and dietary intake of vitamins B2, B6 and B12 with
risk of colorectal adenoma occurrence. We also assessed whether any B-vitamin association
with adenoma risk was modified by folic acid supplementation, baseline plasma folate,
multivitamin use, alcohol use, smoking, age or polymorphisms in key FOCM genes,
methylenetetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR),
methionine synthase (MTR) and cystathionine-β-synthase (CBS).
Methods
Study Design
The Aspirin/Folate Polyp Prevention Study is a randomized, double-blind, placebo-controlled
trial of the efficacy of oral aspirin, folic acid, or both to prevent colorectal adenomas in patients
with a history of adenomas (28). Recruitment began in July 6, 1994 and ended in March 20,
1998. The study was originally designed to investigate the chemopreventive potential of
aspirin. Shortly after enrollment began (after 100 subjects had been randomized), the study
was extended to incorporate folic acid supplementation in a three-by-two factorial design, with
1 mg of folic acid or placebo incorporated into each aspirin treatment arm. The study protocol
was approved by the Institutional Review Board at all 9 clinical centers and written informed
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consent was obtained from all study participants. The findings regarding aspirin and folic acid
have been reported (28,29).
Study Population: Randomization, Interventions and Follow-Up
Eligible individuals had at least one of the following: one or more histologically confirmed
adenomas removed within 3 months before recruitment, one or more histologically confirmed
adenomas removed within 16 months before recruitment and a lifetime history of two or more
confirmed adenomas, or a histologically confirmed adenoma at least 1 cm in diameter removed
within 16 months before recruitment. All participants were required to have had a complete
colonoscopy documenting an absence of lesions remaining in the large bowel within three
months of study entry and anticipated colonoscopy follow-up three years later. After
completion of a 3-month aspirin run-in period, compliant individuals who wished to continue
participating were randomized in a 1:1 ratio to 1 mg per day of folic acid or placebo within
strata defined by clinical center, sex and age (60 years or younger vs. older than 60 years).
Initially three years of treatment and follow-up was planned. However, because of concern that
a longer exposure to folic acid might be required to observe an anti-neoplastic effect (30),
participants were asked to continue on the study treatment for a subsequent (second)
colonoscopic surveillance cycle (usually 3 or 5 years). The present analysis includes 1,084
individuals who completed the first follow-up colonoscopy at least one year after
randomization. When a surveillance colonoscopy was not performed at the end of the first
follow-up interval, we used the last examination at least one year after randomization, on or
before September 28, 2001 was used to demarcate the end of the follow-up period.
Data Collection
Questionnaires—All participants completed a questionnaire regarding personal
characteristics, medical history and lifestyle habits. Dietary information was collected using
the Block food frequency questionnaire administered to participants at baseline. The validity
and reliability of the food frequency questionnaire has been described previously (31).
Questions assessed the average consumption of a food item during the past year. Daily dietary
nutrient intakes were calculated by multiplying frequency responses by the nutrient contents
of the specified portion sizes using a comprehensive database. Brand and type of multivitamin
supplement use were collected. Individuals who regularly consumed multivitamins (at least
once per week) were considered to be “multivitamin users”. Total daily alcohol intake was
calculated as the sum of alcohol content from beer, wine and liquor.
Measurement of Baseline B-Vitamin Levels—Vitamin B assays were conducted at
University of Bergen, Bergen, Norway. Blood samples were collected from non-fasting
participants into 7-ml Vacutainer brand tubes containing EDTA at baseline. After collection,
specimens were immediately put on ice and then centrifuged at 1100 g for 10 minutes. Whole
blood, plasma and buffy coat fractions were stored at -20°C and then transferred to Dartmouth
Medical School where they were stored at -80°C until analysis.
Vitamin B2 (riboflavin) and B6 (pyridoxal 5′phosphate, PLP, the main active form of vitamin
B6 and pyridoxal, PL) were determined in plasma by liquid chromatography-tandem mass
spectrometry and vitamin B12 by microbiological assay using published methods (32,33).
Genotyping Assays—The following polymorphisms were considered in this study:
CBS-1080 C>T, A360A (rs1801181) and CBS-699 C>T, Y233Y (rs234706), MTHFR-677
C>T, V222A (rs1801133) and -1298 C>T, A429E (rs1801131), MTR-2756 A>G, D919G
(rs1805087) and MTRR-66 A>G, I22M (rs1801394). These polymorphisms, selected on the
basis of previous studies suggesting possible biological functions, were genotyped using the
5′nuclease TaqMan allelic discrimination assay on the ABI 7900HT (Applied Biosystems,
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Foster City, CA). All oligo primers and dual-labeled allele discrimination probes were designed
and developed either using Assay-by Design (Applied Biosystem Inc, Foster City, CA) or the
Primer Express software 2.0 (Applied Biosystem). Each assay contained quality control DNAs
of the homozygous wild-type, heterozygous, and homozygous variant alleles for the respective
polymorphisms in addition to the no-target controls. Laboratory staff was blinded to outcome
status. Call rates for each polymorphism were > 98%. Specific experimental details are
available upon request from the authors.
Study Outcomes—Adenoma occurrence was determined by colonoscopy and pathology
review. All important medical events reported by participants were verified with medical
record review. Records for all large bowel procedures (endoscopy or surgery) were
obtained,and slides for all tissue removed from the bowel were retrieved and sent to a single
study pathologist for uniform review. Lesions were classified as neoplastic (adenomatous,
including sessile serrated adenomas) or nonneoplastic.
The primary study outcome was the occurrence of one or more colorectal adenomas detected
at least one year following randomization up to the end of the first follow-up period. A
secondary outcome was the occurrence of one or more advanced lesions, defined as invasive
carcinoma or adenomas with at least 25% villous component, high grade dysplasia, or estimated
size of 1 centimeter or greater.
Statistical Methods
Fisher’s exact and Student’s t tests were used to compare individuals who had an adenoma
occurrence and those that did not with regard to categorical and continuous variables,
respectively. Spearman’s rank correlation coefficient was used to calculate the correlation
between plasma and dietary vitamin-B levels. Baseline plasma quartile (Q) levels of vitamins
B2, B6 and B12 and dietary quartiles levels for vitamins B2 and B6 were the main exposures of
interest. We did not examine dietary vitamin B12 use because it was not estimated by the food
frequency questionnaire software. Overdispersed generalized linear models for the Poisson
family as an approximation to the binomial family were used to compute crude and adjusted
risk ratios to assess the risk of at least one new adenoma. Covariates included in the models
were age, sex, center, duration of follow-up, aspirin treatment group, and baseline multivitamin
use. We included multivitamin use in our final models as an indirect adjustment for other
nutrients/vitamins and unknown lifestyle factors, although exclusion of this variable from
adjusted models did not substantially change any of the results. We also report a fully-adjusted
model including plasma levels or dietary intake of other B-vitamins (including folate). Further
adjustment for BMI, smoking, alcohol use, family history of colorectal cancer, 25-OH vitamin
D levels, dietary calcium intake, dietary methionine, and red meat consumption did not
substantially change the estimated relative risk, and we report here the more parsimonious
models. For plasma measures, we also adjusted for time from blood draw to measurement
(years) to account for possible sample degradation, but this variable was not statistically
significant in any of the regression models nor did the estimates of risk change substantially.
The possibility that baseline factors modified the B-vitamin effect was assessed in these models
with the use of interaction terms and Wald tests (with or without adjustment for other variables).
The following baseline factors were considered: folic acid supplement group (yes vs. no),
plasma folate (above vs. below median), alcohol use (none vs. 1+ drink/day), smoking (never
vs. ever), age (above vs. below median) and multivitamin use (none vs. regular use of at least
once per week). We conducted stratified analysis to obtain stratum specific estimates of risk
and 95% CI. We assessed the potential effect modification of these variables only for the risk
of any adenoma occurrence because of small numbers of advanced lesions.
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We also tested whether there were statistically significant interactions between polymorphisms
in folate genes and B-vitamin plasma/dietary levels on adenoma risk. We considered six
polymorphisms in four key genes coding for enzymes that require vitamins B2, B6 or B12 as
co-factors: CBS-1080 C>T and -699 C>T, MTHFR-677 C>T and -1298 C>T, MTR-2756 A>G
and MTRR-66 A>G. We assessed Hardy-Weinberg equilibrium by using a contingency table
chi-square test to compare observed genotype frequencies to those expected under Hardy-
Weinberg equilibrium. For the majority of polymorphisms, we grouped the heterozygotes with
the common homozygotes, in agreement with findings from previous studies, which suggest
a recessive model for polymorphisms in MTHFR (34,35), MTRR (36) and CBS (37). For
MTR-2756 A/G, we grouped the heterozygotes with the less common homozygote variants to
accomodate limited numbers. For dietary intake of vitamins B2 and B6, we used the median to
define subgroups when examining gene-vitamin B interactions.
All analyses of study folate treatment were conducted according to the principle of intention
to treat. Two-sided p-values less then 0.05 were considered statistically significant. We did not
adjust for multiple testing as per convention in epidemiological studies testing a priori defined
hypotheses. Stata (version 9.2) was used for all analyses.
Results
Characteristics of study participants
Table 1 summarizes the characteristics of the study participants that completed a follow-up
colonoscopy at least one year after randomization. Most were male (n=690, 64%) and the
overall mean age was 57.4 (SD=9.6). Of the 1,084 subjects with endpoint data, 471 (43.5%)
were found to have one or more colorectal adenoma at least one year after randomization.
Subjects with new adenomas did not differ significantly from those without in terms of baseline
dietary and total folate, but were more likely to have lower baseline plasma folate levels
(p=0.025) and consume more alcohol (p=0.006). The mean (SD) time from randomization to
completion of the first follow-up interval was 32.7 (3.6) months.
Correlation between plasma B vitamins
Plasma B-vitamins were significantly correlated with each other. Plasma B2 was modestly
correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45). Plasma
PLP and PL were strongly correlated (rho=0.82) and both were modestly correlated with
plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53,
respectively). Similarly, plasma B12 and folate were modestly correlated (rho=0.34).
Association of baseline B-vitamin plasma and dietary levels and adenoma risk
Baseline PLP concentration was borderline inversely associated with risk of any adenoma (RR
for Q4 vs. Q1=0.78, 95% CI=0.61-1.00, p-trend=0.08, Table 2). However, there was no
association between PLP levels and risk of advanced lesions (RR for Q4 vs. Q1=0.89, 95%
CI=0.46-1.73). Baseline PL levels were also inversely associated with all adenoma risk (RR
for Q4 vs. Q1=0.78; 95% CI=0.62-0.99), an association that was attenuated after further
adjustment for plasma B2, B12 and folate (RR for Q4 vs. Q1=0.86; 95% CI=0.66-1.12). For
advanced lesions, the PL RR for Q4 vs. Q1 was 0.65 (95% CI=0.32-1.32 in a fully adjusted
model). Baseline dietary vitamin B6 intake was modestly correlated with plasma PLP and PL
(rho=0.17 and 0.15, respectively; p<0.001), but did not show any association with risk of any
adenoma (RR for Q4 vs. Q1=1.05; 95% CI=0.78-1.41) or advanced lesions (RR for Q4 vs.
Q1=0.99; 95% CI=0.46-2.12, Table 3). We were also able to examine total B6 intake (diet plus
supplements), and observed non-significant associations similar to those for dietary B6 (data
not shown).
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Baseline plasma vitamin B2 was not significantly associated with adenoma risk (adjusted RR
for Q4 vs. Q1=0.95, 95% CI=0.75-1.20) although there was a statistically significant inverse
association for advanced lesions (RR for Q4 vs. Q1=0.51, 95% CI=0.26-0.99, p-trend=0.12,
Table 2). Baseline dietary vitamin B2 was modestly correlated with plasma levels (rho=0.1;
p<0.001), and showed a borderline non-significant inverse association with risk of all
adenomas (RR for Q4 vs. Q1=0.83; 95% CI=0.64-1.08, Table 3), but not with advanced lesions
(RR for Q4 vs. Q1=0.78; 95% CI=0.39-1.57, Table 3).
There was no significant association between baseline plasma B12 and risk of any adenoma
(RR for Q4 vs. Q1=0.91, 95% CI=0.73-1.15) or advanced lesions (RR for Q4 vs. Q1=0.94,
95% CI=0.52-1.69, Table 2).
When we examined multivitamin use with adjustment for plasma vitamins B2, B6 and B12 and
folate, we observed no association with any adenoma (RR for Q4 vs. Q1=1.02; 95%
CI=0.85-1.23) or advanced lesions (RR for Q4 vs. Q1=1.07; 95% CI= 0.66-1.73).
Effect modification of folic acid treatment group, baseline plasma folate, age, smoking,
multivitamin and alcohol use at baseline
Table 4 provides estimates of risk for any adenoma according to baseline plasma B2, B6 and
B12 stratified by folic acid treatment group, multivitamin use and alcohol use. There was no
evidence that folic acid supplementation modified the association between any plasma B
vitamin and adenoma risk (Table 4). In addition, baseline plasma folate levels did not modify
the associations of plasma vitamin B2 (p-interaction=0.75), PLP (p-value for interaction=0.69),
PL (p-value for interaction=0.68) or vitamin B12 (p-value for interaction=0.19) with adenoma
risk (data not shown). Similarly, multivitamin use at baseline did not significantly modify the
association between plasma B2, B6 (PLP and PL) or B12 and adenoma risk. However, alcohol
use did appear to interact significantly with the association of PLP and risk of all adenomas:
the inverse association was evident only in non-drinkers (p-value for interaction=0.03). No
other significant interactions with PL or dietary B2 or B6 were observed. Smoking status and
age did not significantly modify any of the associations with plasma or dietary intake of B2,
B6 or B12 (all p-interactions>0.05).
Selected gene-nutrient interactions and adenoma risk
There was no evidence of deviation from Hardy-Weinberg equilibrium for any of the
polymorphisms investigated. As previously reported by us, MTHFR -C677T and MTHFR-
C1298T were not significantly associated with adenoma risk in adjusted models (38). The
relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66
G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it
was 0.80 (95% CI=0.62-1.03). We observed a significantly increased risk for any adenoma
recurrence among individuals with the CBS-1080 T/T genotype compared to those with at least
one C allele (RR=1.29, 95% CI=1.06-1.56).
There was a suggestive, but non-significant, interaction between the MTHFR- C677T
polymorphism and baseline plasma vitamin B2 on risk of all adenomas (Table 5). Among
subjects who were homozygotes for the (variant) T allele there was a non-significantly
increased risk of adenomas associated with higher plasma vitamin B2 (adjusted RR=1.40; 95%
CI=0.85-2.30), while those who were heterozygotes or homozygotes for the common 677C
allele showed a reduced risk (adjusted RR=0.87; 95% CI=0.73-1.03, p-interaction=0.07). The
association between baseline median dietary vitamin B2 levels and adenoma risk did not
significantly differ by MTHFR-677C/T or -1298C/T genotypes (data not shown).
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There was no indication that the risk of adenomas associated with baseline plasma vitamin
B12 differed by MTHFR-677C/T, MTR-2756A/G or MTRR-66A/G genotypes or that the
association between baseline plasma vitamin B6 (PLP or PL (data not shown)) and adenoma
risk differed by MTHFR-677C/T, CBS-1080C/T or -699C/T genotypes. Baseline dietary levels
of vitamin B6 also showed no evidence of effect modification by these genotypes (data not
shown).
Discussion
In this randomized clinical trial of aspirin use and folic acid supplementation, we found a
borderline significant inverse association between baseline plasma vitamin B6 (PLP, the active
form of B6) levels and risk of all adenomas, but not advanced lesions. The inverse association
was not modified by folic acid supplementation or baseline plasma folate, although we did
observe a significant interaction between plasma PLP levels and alcohol use. Dietary and total
intake of B6 as well as plasma B12 were not associated with risk of adenomas or advanced
lesions. Circulating levels of B2 were inversely associated with risk of advanced lesions, while
dietary intake showed a non-significant inverse trend for all adenomas. There were no
significant interactions between polymorphic FOCM genes and their respective B vitamin co-
factors, except possibly for MTHFR-C677T and plasma B2.
In FOCM, vitamin B6 acts as a co-factor for serine hydroxyl-methyltransferase (SHMT), which
catalyzes the formation of glycine and 5,10-methylenetetrathydrofolate, a key carrier of one
carbon groups in nucleotide synthesis and DNA repair. In addition, vitamin B6 is a co-factor
for CBS, which catalyzes the irreversible conversion of homocysteine to cystathionine,
reactions that may affect intracellular SAH levels in vivo (39). Vitamin B6 is also involved in
nearly 100 enzymatic reactions (40) and has been shown to reduce oxidative stress as well as
cell proliferation and angiogenesis (41,42), all effects that could result in reduced risks of
neoplasia. Vitamin B6 is found in poultry, fish, liver, whole grains, nuts and legumes, and
deficiency has been associated with impaired FOCM (43) and chemically induced colon tumor
formation in animal models (41).
In contrast to our results for plasma levels, we found no statistically significant association of
baseline dietary vitamin B6 with adenoma occurrence. Other observational studies have
reported an inverse relationship between dietary vitamin B6 intake and risk of colorectal
adenomas (3,4) and a more consistent association with cancer (7,12-17). Our negative results
could have been due to measurement error in the estimation of intake, which would tend to
exert a conservative bias (44). We are aware of only one other study that examined plasma
vitamin B6 (PLP) levels and colorectal adenoma and cancer risk. Wei and colleagues showed
a significant inverse association for PLP and risk of colon cancer and a borderline significant
risk of incident advanced distal colorectal adenomas among women (14).
Previous studies have investigated the possible interaction between polymorphisms in MTHFR
and dietary intake of vitamin B6 on risk of colorectal cancer and adenomas. A stronger
protective effect of vitamin B6 on adenoma risk has been observed among individuals with the
MTHFR-677 T/T genotype compared to those with at least one C allele (6,20,21), though this
interaction was statistically significant in only one study (6). There has been no previous
investigation regarding interactions between plasma or dietary vitamin B6 and two functional
polymorphisms in the B6-dependent CBS enzyme (i.e., CBS-699C/T and -1080C/T) (45) on
risk of adenomas.
Vitamin B2 (found in dairy products, poultry, fish, grains and enriched food products) is the
precursor for flavin mononucleotide and flavin adenine dinucleotide (FAD), key cofactors in
multiple oxidation/reduction reactions including the reduction of 5,10-MTHF to 5-MTHF,
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catalyzed by MTHFR (46). Our data did not suggest a significant association between plasma
riboflavin levels and risk of any adenoma, although we observed a borderline significant
inverse association with risk of advanced lesions, and suggestive associations with dietary
intake. Other studies have also reported non-significant associations of dietary vitamin B2 with
risk of colorectal adenomas (3-7). The only study to observe a significant protective effect of
dietary B2 was a case-control study of colorectal adenomas in the Netherlands (8). Contrary
to the Netherlands, foods in the U.S. have been enriched with vitamin B2 since 1940s (47).
Thus, our study population may have relatively high B2 intake (48), leaving us with insufficient
variation in our population to observe significant associations.
We also investigated whether the MTHFR-677C/T polymorphism modified the relationship
between plasma levels of vitamin B2 and adenoma risk. The MTHFR-677 T allele codes for a
valine at position 222 in the FAD binding domain of the enzyme and the variant enzyme has
relatively lower affinity for the FAD cofactor (49,50) suggesting that a high level of the FAD
cofactor may stabilize the variant enzyme just as folate does (51,52). However, we observed
a non-significant increase in adenoma risk for those with the MTHFR-677T/T genotype and
plasma B2 levels above the median compared to those with that genotype and lower plasma
B2 levels. There was a borderline significant association between plasma B2 and any adenoma
occurrence among those with at least one C allele. These findings contrast with a report that
dietary intake of B2 is inversely associated with adenoma risk in those with the MTHFR-677T/
T genotype (8). Other studies found no evidence of interaction between dietary vitamin B2 and
MTHFR 677C>T on risk of colorectal adenomas (3,8) or cancer (5). When we examined dietary
vitamin B2 levels and adenoma risk there was no suggestion of effect modification by the
MTHFR-677C/T genotype.
Vitamin B12 is a co-factor of MTR, which, paired with MTRR, catalyzes transfer of methyl
groups from 5-MTHF to homocysteine via vitamin B12. Vitamin B12 is found exclusively
animal products, and deficiencies of either enzyme or the B12 cofactor essentially trap 5-MTHF
molecules at the B12 transfer step (53). In agreement with our findings, the majority of studies
for both adenoma (3,8,11) and cancer risk (5,6,10,12) have found no evidence of an association
with dietary vitamin B12. There has been considerable study of the role of polymorphisms in
MTR-2756A>G and MTRR-66A>G, including assessment of their interaction with vitamin
B12 in colorectal neoplasia (6,22,26,54-57). The MTRR-A66G variant allele has been
associated with a lower affinity for MTR and possibly less efficient reducing capacity (58),
while the MTR-A2756G polymorphism has been inconsistently reported to affect plasma
homocysteine and folate levels (59,60). Data regarding MTRR-G66 have been inconsistent in
this regard (5,6,26,61,62). As in our study, the MTR-2756A->G polymorphism does not appear
to play a role in colorectal carcinogenesis (22,54,57). Additionally our data are consistent with
other studies (6,20) that have found no evidence of interaction between MTHFR-677C->T and
B12.
In agreement with our findings, other investigations have not found that folate status modified
the association of plasma or dietary vitamin B intakes with risk of colorectal neoplasia. The
Nurses’ Health Study did not find a statistically significant stronger protective effect of high
PLP levels among individuals with low plasma folate, non-users of multivitamins or B-vitamin
supplements on colorectal cancer or adenoma risk (14). At least one other study also failed to
observe a significant interaction between intakes of vitamins B2, B6 and B12 and dietary folate
on risk of colorectal adenomas (3). These data may reflect limited statistical power to detect
interaction, but may also suggest that PLP may protect against colorectal neoplasia through
biological pathways other than FOCM. We observed a potential interaction between PLP and
alcohol. Alcohol is a known folate “antagonist” that affects dietary methyl supply. In addition
to effects on folate availability, alcohol is metabolized into acetaldehyde, which has been
shown to be carcinogenic in the colorectum possibly through inhibition of DNA methylation
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and interactions with retinoid metabolism (63). Findings from two other studies (12,13)
observed a protective effect of vitamin B6 among heavy drinkers, and further study is need to
better understand these relationships.
This study has several limitations. The generalizability of our results may be limited as all
participants in this clinical trial were volunteers who had a previous history of at least one
colorectal adenoma and so represent a restricted part of the colon cancer risk spectrum. We
had a limited sample size to investigate risk of advanced lesions, a clinically important
endpoint. We used a validated semi-quantitative food frequency questionnaire, but these are
still subject to measurement error, which may introduce substantial biases, generally
conservative (44). Also, we did not consider all polymorphisms in CBS, MTR, MTRR and
MTHFR, and we do not have any information on other key polymorphic FOCM genes. For
example, serine hydroxymethyltransferase (SHMT) is a vitamin B6 dependent enzyme
involved in purine and pyrimidine nucleotide synthesis, and previous investigation has
suggested a potential interaction between the SHMT-1420C>T polymorphism and dietary
levels of vitamin B6 in colorectal adenoma risk (19).
Strengths of this study include the measurement of baseline plasma vitamin B levels (though
in non-fasting bloods), genotypes in key FOCM genes and the large sample size. Because of
the prospective design, recall or selection biases are unlikely to explain our findings in this
study. In addition, inclusion only of individuals with a clean colonoscopy in this prospective
clinical trial allowed us to assess the effect of B-vitamins on incident rather than prevalent
adenomas, and thereby to make clear the temporal relationships between intake and adenoma
occurrence. Furthermore, the high follow-up rates in this study (29) minimizes the concern that
differential rates of follow-up affected our results.
In summary, our results suggest that high baseline levels of PLP and B2 may protect against
new colorectal adenomas among individuals with a previous history of adenomas.
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Table 1
Characteristics of individuals in the Polyp Prevention Trial of Aspirin and Folate who completed first year follow-up
Characteristic Adenoma occurrence No adenoma occurrence p-value**
No. of participants 471 613
Age at baseline, mean ± SD (y) 59.0 ± 9.3 56.2 ± 9.6 <0.001#
Male Sex, No. (%) 321 (68.2%) 369 (60.2%) 0.007
Body-mass index > 30 kg/m2, No. (%) 117 (24.9%) 125 (20.4%) 0.080
Current cigarette smoker, No. (%) 86 (18.5%) 72 (11.8%) 0.002
Colorectal cancer in first-degree relative, No. (%) 143 (37.1%) 189 (37.4%) 0.949
Self identified as White, No. (%) 412 (87.5 %) 516 (84.2%) 0.125
Aspirin use at baseline, No. (%) 291 (61.8%) 358 (58.5%) 0.274
Aspirin Treatment Group¥, No. (%) 300 (63.7%) 421 (68.7%) 0.085
Folate Treatment Group, No. (%) 221 (51.8%) 280 (50.0%) 0.584
Baseline plasma folate, mean ± SD (nmol/L) 21.9 (15.3%) 24.4 (19.1%) 0.025#
Baseline plasma B2, mean ± SD 30.6 ± 56.8 27.7 ± 43.6 0.374#
Baseline plasma B6, mean ± SD 76.3 ± 89.2 81.3 ± 86.8 0.378#
Baseline plasma B12, mean ± SD 317.1 ± 141.3 333.7 ± 177.1 0.112#
Multivitamin use, No. (%) 153 (32.6%) 226 (37.1%) 0.125
Dietary intake
Dietary folate intake, mean ± SD (mg/day) 317.9 ± 150.4 320.7 ± 162.4 0.772#
Total folate*, mean ± SD (mg/day) 460.2 ± 309.5 461.9 ± 284.7 0.927#
Dietary vitamin B2 
†, mean ± SD ((mg/day) 30.6 ± 56.8 27.7 ± 43.6 0.729#
Total vitamin B6
*, mean ± SD (mg/day) 2.6 ± 2.2 2.5 ± 2.0 0.718#
Total vitamin B12 
‡, mean ± SD (mg/day) 2.6 ± 5.8 2.5 ± 4.6 0.779#
Alcohol (drinks per day), No (%)
 None 121 (26.8%) 206 (35.4%) 0.006
 1 or less 223 (49.4%) 271 (46.6%)
 2 or more 107 (23.7%) 105 (18.0%)
Adenoma Characteristics (at baseline)§
Number (mean ± SD) 1.7 ± 1.1 1.5 ± 0.9 <0.001#
Large Adenomas (>1 cm), No. (%) 107 (22.7%) 140 (22.8%) 0.962
Villous histology, No. (%) 60 (12.7%) 93 (15.2%) 0.254
Proximal location, No. (%) 248 (52.7%) 244 (39.8%) <0.001
¥
81 and 325 mg/day aspirin treatment groups combined
*
Total folate and total B6 = dietary + supplements
†
Total B2 from dietary sources only
‡
Total B12 from supplements only
§
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Table 5









CI)* P for interaction
Baseline plasma vitamin B2
(riboflavin) 2.1-15.0 nmol/L 15.1-479.0 nmol/L
MTHFR-677 CC+C/T 195/413 179/416 0.87 (0.73-1.03)
MTHFR-677 T/T 18/52 19/44 1.40 (0.85-2.30) 0.07
MTHFR-1298 A/A+A/C 197/431 178/416 0.90 (0.76-1.07)
MTHFR-1298 C/C 16/35 21/45 0.92 (0.56-1.54) 0.94
Baseline plasma vitamin B6 (PLP) 21.4-300.3 pmol/L 300.5-2479 pmol/L
CBS-1080 C/C+C/T 182/403 159/402 0.90 (0.75-1.08)
CBS-1080 T/T 37/56 32/62 0.72 (0.49-1.03) 0.25
CBS-699 C/C+C/T 195/404 179/422 0.89 (0.75-1.06)
CBS-699 T/T 25/57 13/44 0.67 (0.40-1.13) 0.30
MTHFR-677 CC+C/T 196/410 178/419 0.90 (0.76-1.07)
MTHFR-677 T/T 24/51 13/45 0.66 (0.39-1.10) 0.25
Baseline plasma vitamin B12 4.7-53.3 nmol/L 53.4-857.0 nmol/L
MTR 2756-A/A 72/155 63/151 0.92 (0.71-1.20)
MTR 2756- A/G + G/G 151/310 127/314 0.87 (0.72-1.05) 0.70
MTRR 66-A/A+A/G 163/335 139/342 0.86 (0.72-1.03)
MTRR 66-G/G 59/129 51/123 0.96 (0.72-1.29) 0.50
MTHFR-677 CC+C/T 198/411 177/421 0.90 (0.77-1.07)
MTHFR-677 T/T 24/52 13/45 0.69 (0.41-1.17) 0.33
*
Adjusted for age, sex, center, duration of follow-up, aspirin treatment group, multivitamin use and plasma B2, B6, B12 and folate as appropriate
¥
p-value for interaction
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